Advanced disease progression occurred less often with vutrisiran than placebo in both the overall population (8.0% vs 10.7%) and monotherapy subgroup (8.2% vs 11.1%). Transition to NYHA class IV was ...
Nancy L. Lewis, MD, MBS, FACP, reflects on the career journey that led her to her new role as chief scientific officer (CSO) ...
When a woman is diagnosed with breast cancer, the clinical machinery swings into motion: imaging, staging, oncology referrals ...
Susan Cantrell, CEO of AMCP, explained in an interview with The American Journal of Managed Care® ( AJMC®) that the ...
Tirzepatide (Mounjaro; Eli Lilly), a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide ...
Why Medicaid-covered kids struggle to see pediatricians: low reimbursement and practice deserts in low-income ZIP codes ...
Clinically significant insomnia, elevated OSA risk, and insufficient sleep duration were markedly higher in rural Appalachian ...
These findings, reported in 2 posters presented at the 2026 American Academy of Dermatology Annual Meeting, highlight ...
Among the most striking findings, 86.1% of patients treated with bimekizumab were completely flare-free across the entire ...
When asked about behavioral support, 56% of employed adults said they would self-pay for a GLP-1 if their employer offered a ...
Repeated noninvasive stool DNA testing could offer greater real-world effectiveness than colonoscopy for colorectal cancer ...
Her career has taken her from treating patients to developing new medicines for biopharma, and now Nancy L. Lewis, MD, MBS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results